
Sign up to save your podcasts
Or
In this week's episode we’ll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL.
Featured Articles:
4.1
4646 ratings
In this week's episode we’ll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL.
Featured Articles:
127 Listeners
73 Listeners
314 Listeners
26 Listeners
477 Listeners
91 Listeners
1,086 Listeners
174 Listeners
745 Listeners
511 Listeners
319 Listeners
364 Listeners
2 Listeners
166 Listeners
49 Listeners